Medirom Total Revenue vs Ebit Per Revenue Analysis
MRM Stock | USD 3.01 0.02 0.67% |
Medirom Healthcare financial indicator trend analysis is infinitely more than just investigating Medirom Healthcare recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Medirom Healthcare is a good investment. Please check the relationship between Medirom Healthcare Total Revenue and its Ebit Per Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Total Revenue vs Ebit Per Revenue
Total Revenue vs Ebit Per Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Medirom Healthcare Total Revenue account and Ebit Per Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Medirom Healthcare's Total Revenue and Ebit Per Revenue is -0.29. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Ebit Per Revenue in the same time period over historical financial statements of Medirom Healthcare Technologies, assuming nothing else is changed. The correlation between historical values of Medirom Healthcare's Total Revenue and Ebit Per Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Medirom Healthcare Technologies are associated (or correlated) with its Ebit Per Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit Per Revenue has no effect on the direction of Total Revenue i.e., Medirom Healthcare's Total Revenue and Ebit Per Revenue go up and down completely randomly.
Correlation Coefficient | -0.29 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Revenue
Total revenue comprises all receipts Medirom Healthcare generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Ebit Per Revenue
Most indicators from Medirom Healthcare's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Medirom Healthcare current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Medirom Healthcare's Enterprise Value Over EBITDA is very stable compared to the past year. As of the 26th of November 2024, Enterprise Value Multiple is likely to grow to 25.56, while Selling General Administrative is likely to drop about 1.4 B.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 151.5M | 184.1M | 252.6M | 135.8M | Interest Income | 839K | 6.1M | 1.1M | 2.0M |
Medirom Healthcare fundamental ratios Correlations
Click cells to compare fundamentals
Medirom Healthcare Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Medirom Healthcare fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.8B | 5.7B | 5.8B | 6.7B | 6.8B | 6.3B | |
Short Long Term Debt Total | 2.4B | 1.9B | 2.8B | 2.5B | 3.6B | 2.9B | |
Other Current Liab | 581.4M | 1.7B | 1.9B | 2.6B | 2.1B | 1.7B | |
Total Current Liabilities | 2.3B | 2.7B | 3.2B | 3.6B | 3.6B | 3.2B | |
Total Stockholder Equity | 600.1M | 491.3M | (208.3M) | (59.4M) | 210.9M | 122.3M | |
Property Plant And Equipment Net | 2.0B | 1.8B | 2.2B | 2.4B | 2.5B | 2.4B | |
Current Deferred Revenue | 483.1M | 442.4M | 104.2M | 89.0M | 512.0M | 287.1M | |
Net Debt | 1.8B | 463.8M | 2.4B | 1.9B | 3.5B | 2.3B | |
Retained Earnings | (705.3M) | (1.7B) | (2.7B) | (2.5B) | 80.3M | 84.3M | |
Accounts Payable | 122.6M | 67.0M | 230.9M | 207.6M | 137.7M | 166.3M | |
Cash | 513.6M | 1.4B | 370.6M | 605.5M | 106.3M | 101.0M | |
Non Current Assets Total | 3.4B | 3.6B | 4.4B | 4.4B | 5.1B | 4.5B | |
Non Currrent Assets Other | 987.3M | 1.6B | 107.2M | 1.0B | 1.1B | 749.7M | |
Long Term Debt | 150.5M | 668.4M | 746.6M | 1.1B | 1.1B | 753.3M | |
Cash And Short Term Investments | 552.1M | 1.5B | 397.1M | 606.0M | 106.8M | 101.5M | |
Net Receivables | 773.6M | 148.5M | 855.3M | 534.7M | 621.9M | 476.9M | |
Good Will | 78.3M | 150.7M | 600.3M | 539.5M | 484.6M | 351.5M | |
Short Term Investments | 38.5M | 32.5M | 26.5M | 500K | 450K | 427.5K | |
Liabilities And Stockholders Equity | 4.8B | 5.7B | 5.8B | 6.7B | 6.8B | 6.3B | |
Non Current Liabilities Total | 1.9B | 2.6B | 2.8B | 3.2B | 3.1B | 2.9B | |
Capital Lease Obligations | 1.8B | 1.7B | 1.9B | 2.0B | 2.1B | 2.1B | |
Inventory | 5.5M | 8.0M | 18.7M | 114.1M | 140.0M | 147.0M | |
Other Current Assets | 47.5M | 458.5M | 111.2M | 1.1B | 890.0M | 486.9M | |
Total Liab | 4.2B | 5.2B | 6.0B | 6.8B | 6.6B | 6.1B | |
Net Invested Capital | 1.1B | 1.3B | 700.5M | 1.2B | 1.8B | 1.2B | |
Property Plant And Equipment Gross | 2.0B | 183.1M | 2.4B | 2.6B | 2.8B | 2.3B | |
Short Long Term Debt | 371.6M | 221.1M | 162.3M | 99.2M | 500.4M | 525.4M | |
Total Current Assets | 1.4B | 2.1B | 1.4B | 2.4B | 1.8B | 1.8B | |
Non Current Liabilities Other | 5.6M | 348.4M | 25.2M | 335.0M | 271.7M | 182.0M | |
Net Working Capital | (884.0M) | 428.3M | (1.8B) | (1.3B) | (1.8B) | (1.9B) | |
Short Term Debt | 1.1B | 900.6M | 917.5M | 868.9M | 1.3B | 827.8M | |
Intangible Assets | 77.6M | 97.6M | 391.0M | 403.7M | 920.7M | 966.7M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.582 | Earnings Share (0.15) | Revenue Per Share 1.4 K | Quarterly Revenue Growth (0.06) | Return On Assets (0.04) |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.